Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Société Générale M&A Activity 2020

Apr 28, 2020

1671_mrq_2020-04-28_eb9ea41d-deba-402b-a4da-8ba6a3296c05.html

M&A Activity

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 1368L

Societe Generale SA

28 April 2020

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1) Société Générale S.A.
Company dealt in Allergan plc
Class of relevant security to which the dealings being disclosed relate (Note 2) US$0.0001 ordinary shares
Date of dealing 27/04/2020

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long Short
Number (%) Number (%)
(1) Relevant securities 3,311,817 1.01 42,911 0.01
(2) Derivatives (other than options) 0 0.00 3,033,991 0.92
(3) Options and agreements to purchase/sell 58,500 0.02 0 0.00
Total *8,210,053 *2.49 3,076,902 0.93

* Include the holding of 4,839,736 shares on borrow products

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale Number of relevant securities Price per unit USD (Note 5)
Purchase 100 188.01
Purchase 74 187.6
Purchase 26 187.6
Purchase 100 187.84
Purchase 100 187.77
Purchase 95 187.41
Purchase 5 187.41
Purchase 100 187.63
Purchase 100 188.17
Purchase 578 188.24
Purchase 200 188.24
Purchase 100 188.25
Purchase 100 188.13
Purchase 100 188.03
Purchase 400 188.24
Purchase 100 187.62
Purchase 100 187.98
Purchase 100 188.25
Purchase 100 187.66
Purchase 100 187.39
Purchase 99 188.08
Purchase 164 188.15
Purchase 36 188.15
Purchase 100 188.15
Purchase 10 187.65
Purchase 90 187.65
Purchase 100 187.83
Purchase 100 188.03
Purchase 374 188.24
Purchase 100 187.64
Purchase 100 188.24
Purchase 2,800 187.803129
Purchase 500 175.8426
Sale 544 187.04
Sale 187 187.349572
Sale 24 188.24
Sale 100 187.88
Sale 100 187.61
Sale 100 187.48
Sale 100 187.66
Sale 100 187.48
Sale 5 187.48
Sale 95 187.48
Sale 100 187.78
Sale 100 187.68
Sale 100 187.89
Sale 16 187.35
Sale 99 187.31
Sale 100 187.27
Sale 249,102 188.24
Sale 56 187.67
Sale 44 187.67
Sale 100 187.6
Sale 100 187.78
Sale 77 188.24
Sale 100 187.8
Sale 100 187.56
Sale 100 187.84
Sale 100 187.85
Sale 72 187.83
Sale 28 187.83
Sale 100 187.93
Sale 100 187.77
Sale 100 187.65
Sale 100 187.6
Sale 100 187.7
Sale 100 187.6
Sale 100 187.84
Sale 100 187.54
Sale 100 187.74
Sale 100 187.71
Sale 100 187.7
Sale 100 187.87
Sale 100 187.63
Sale 100 187.64
Sale 100 187.84
Sale 100 187.79
Sale 100 187.91
Sale 100 187.89
Sale 100 187.91
Sale 100 187.91
Sale 149 187.290134
Sale 898 188.24
Sale 231 188.06
Sale 131 188.06
Sale 231 188.06
Sale 231 188.06
Sale 153 188.06
Sale 231 188.06
Sale 231 188.06
Sale 104 188.24
Sale 231 188.06
Sale 751 188.06
Sale 231 188.06
Sale 231 188.06
Sale 224 188.06
Sale 231 188.06
Sale 231 188.06
Sale 29 188.24
Sale 123 188.24
Sale 421 188.24
Sale 1,577 188.24
Sale 1,765 188.24
Sale 231 188.24
Sale 231 188.06
Sale 8 187.9755
Total Purchases 7,251
Total Sales 262,954

(b)      Derivatives transactions (other than options transactions)

Product name,

e.g. CFD
Nature of transaction

(Note 6)
Number of relevant securities

(Note 7)
Price per unit USD

(Note 5)
Equity Linked Swap Decreased short 249,102 188.24
Equity Linked Swap Decreased short 898 188.24

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name,

e.g. call option
Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name,

e.g. call option
Number of securities Exercise price per unit (Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)
Details Price per unit

(if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any 

relevant securities to which any derivative referred to on this form is referenced. 

If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            Yes

Date of disclosure 28/04/2020
Contact name Société Générale - Disclosure team
Telephone number +33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap23

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL 

ACT, 1997, TAKEOVER RULES, 2013

DETAILS OF OPEN POSITIONS

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

OPEN POSITIONS (Note 1)

Product name,

e.g. call option
Written, or purchased Number of relevant securities to which the option or derivative relates Exercise price (Note 2) Type, e.g. American, European etc. Expiry date
Listed Put Option Sale 40,000 175 American options 15/01/2021
Listed Put Option Sale 18,500 190 American options 15/01/2021

Notes

1.          Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

2.          For all prices and other monetary amounts, the currency must be stated.

For full details of disclosure requirements, see Rule 8 of the 

Rules. If in doubt, consult the Panel.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

ISEKKFBNOBKKOQB